Introduction
Venlafaxine is a phenethylamine bicyclic derivative, chemically unrelated to tricyclic, tetracyclic or other available antidepressant agents (Fig. 1 ). The mechanism of venlafaxine's antidepressant action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system (CNS). Preclinical studies have shown that venlafaxine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake, and a weak inhibitor of dopamine reuptake. 1 Venlafaxine is well absorbed, with peak plasma concentrations occurring approximately 2 h after dosing. Venlafaxine is extensively metabolized, with Odesmethylvenlafaxine (ODV, the only major active metabolite), peak plasma levels occurring approximately 4 h after dosing. Most common side effects include: nausea, constipation, anorexia, vomiting, dizziness, insomnia, nervousness, abnormal dreams, anxiety, tremor and abnormal vision. 1 The most commonly used analytical methods for the determination of venlafaxine include separation techniques, such as high-performance liquid chromatography with either UV [2] [3] [4] [5] [6] [7] or fluorometric 8, 9 detection and capillary electrophoresis 10, 11 including micellar electrokinetic chromatography. 12 The above-mentioned techniques offer a high-resolution and selectivity tool when the analyte has to be monitored in complex biological matrices, such as blood and urine. However, in quality-control tests of pharmaceutical formulations during production, flow-injection (FI) analysis offers the advantages of rapidity, simplicity and lack of organic solvents containing waste, compared to HPLC. To the best of our knowledge, no FI method has been reported so far for the determination of venlafaxine.
The scope of the present study is to develop a simple, fast and reliable FI method for the determination of venlafaxine in its formulations, based on a direct measurement of the absorbance of the analyte in an acidic medium at 274 nm. The method was optimized and validated for dissolution studies of venlafaxine tablets from a production validation process. No additional pretreatment of the samples was required prior to analysis, accelerating in this way the quality-control process. The accuracy of the assay was evaluated by analyzing synthetic samples and by comparing the dissolution results obtained from FI to HPLC.
Experimental

Reagents
All chemicals were provided by Merck (Germany), unless The first flow-injection method has been developed, optimized and validated for the determination of venlafaxine, an antidepressant drug. The method is based on a direct measurement of the absorbance of the analyte in an acidic medium, at 274 nm. Flow-injection parameters, such as sample injection volume and flow rate, were studied and optimized. The proposed method was validated in terms of linearity, repeatability, detection limit, accuracy and selectivity. Linearity was obeyed in the range 30 -150 mg L -1 of venlafaxine, while the detection limit (1.5 mg L -1 ) and repeatability (sr < 1.0%, n = 12) were satisfactory. The sampling rate was 30 h -1 . The results of dissolution studies of venlafaxine tablets obtained by the proposed method were in good agreement with those by high-performance liquid chromatography. stated otherwise. Purified water (κ < 4.3 µS cm -1 ) was used for preparing solutions.
A venlafaxine hydrochloride working standard (Lot No.: 051w21001) was provided by Seloc (France).
Standard working solutions were prepared by dissolving appropriate amounts of the working standard in 0.1 mol L -1 HCl.
The pharmaceutical excipients for preparing a placebo mixture (colloidal silica anhydrous, dicalcium phosphate, croscarmellose and magnesium stearate) were provided by domestic suppliers.
Instrumentation
The FI setup used in this work is depicted in Fig. 2 . The hardware (pump, injection valve, autosampler and detector) of an HP1100 (Hewlett Packard) instrument was used throughout the experiments. A 10-cm long/0.28 mm i.d. PTFE mixing coil was used for FI, while a Hypersil BDS C18 column (250 × 4 mm/5 µm) was used for HPLC measurements. Data acquisition (peak height and peak area for FI and HPLC, respectively) was performed via Chem Station ® software.
A Distek Premiere 5100 system equipped with an autosampler was used for dissolution experiments.
FI procedure for aqueous solutions
Thirty microliters of venlafaxine standards (30 -150 mg L -1 ) or samples were injected via an autosampler to a 0.1 mol L -1 HCl carrier stream. The sample zone was propelled at a flow rate of 1.0 ml min -1 through a 10-cm long mixing coil towards the diode-array photometric detector. The peak height was used for quantitative measurements, while each standard/sample was injected in triplicate.
Dissolution studies of venlafaxine tablets
Four batches of venlafaxine tablets were tested. Batches No. 37050401 and 37050402 contained 37.5 mg of venlafaxine per tablet, while batches 75050401 and 75050402 contained 75 mg of venlafaxine per tablet. The working dissolution parameters are given in Table 1 . Six tablets from each batch were weighed and introduced to the dissolution apparatus. The dissolution profile of each formulation was recorded as automated sampling was performed at 5, 10, 15 and 30 min.
Determination of venlafaxine by HPLC
In order to evaluate the accuracy of the developed method, the samples from the dissolution studies were analyzed using highperformance liquid chromatography.
The mobile phase consisted of a (30:70 v/v) mixture of ACN and buffer solution (4.0 ml trifluoroacetic acid and 7.0 ml triethylamine to 1 L of water, pH = 3.0). The flow rate was 1.0 ml min -1 , the injection volume 10 µL, the column temperature 25˚C and the detection wavelength 274 nm. A Hypersil BDS C18 column (250 × 4 mm/5 µm) was used throughout the experiments. Under the above-mentioned conditions, the retention time of the analyte was ca. 10 min.
Results and Discussion
Preliminary studies
A single-line manifold was chosen for FI experiments. Since the dissolution medium of the samples was 0.1 mol L -1 HCl, the same medium was used as a carrier in order to minimize any matrix effects. Under acidic conditions, venlafaxine showed an absorption maximum at 274 nm (Fig. 3) , which was used for further experiments.
Optimization of the injection volume and the flow rate
The sample-injection volume and the carrier flow rate were studied and optimized at three venlafaxine concentrations, namely 50, 100 and 150 mg L -1 . The starting values of these variables were 10 µL and 0.6 ml min -1 , respectively.
The effect of the volume of the injected venlafaxine was studied in the range 10 -100 µL. An increase of the sample volume resulted in a non-linear increase of the signals. This was expected, since the volume of the sample injected in a FI system is inversely proportional to the dispersion of the sample zone. Better results compromising among linearity, sensitivity and precision were obtained at 30 µL. This value was selected for further experiments.
The carrier flow rate (0.4 -1.2 ml min -1 ) had little effect on the sensitivity of the determination, because it does not significantly contribute to dispersion in single-channeled manifolds. However, better precision and base-line stability were obtained at 1.0 ml min -1 . It should be noted that the sampling rate was not affected by the flow rate of the carrier stream. In all cases, the sampling rate was controlled by the cycle injection time of the HP 1100 autosampler, which was 2 min. Thus, the "real" maximum sampling rate was 30 h -1 , regardless the geometry of the FI manifold (the peaks were 1516 ANALYTICAL SCIENCES DECEMBER 2005, VOL. 21 completed within 30 s).
Linearity, limit of detection and precision
As shown in Table 1 , the volume of the dissolution medium was 500 ml for the 37.5 mg/tab strength and 750 ml for the 75 mg/tab strength of the venlafaxine formulations. For this reason, the theoretical final concentrations of the real samples would be 75 and 100 mg L -1 . In order to "bracket" the abovementioned levels, the linearity of the developed assay was examined in the range 30 to 150 mg L -1 (n = 8). The experimental results showed that the method was linear within the studied range, obeying the regression equation mA.U. = 1.861(±0.009)γ (venlafaxine) + 2.076(±0.940) with a correlation coefficient of 0.9999. The validity of the calibration curve was evaluated by a response factor (r.f.) test [r.f. = mA.U. -2.076/γ (venlafaxine)] at each point of the calibration curve. 13 The results verified the validity of the regression line, since the deviations response factors were in the range ±0.9% of the "calibration curve value" (1.861).
The detection limit of the developed FI method was estimated by the equation LOD = 3 × si/S, were si is the standard deviation of the intercept and S is the slope of the regression curve. 14 The LOD was calculated to be 1.5 mg L -1 , which is satisfactory for this type of analysis.
The precision of the proposed assay was studied by repeatability experiments (within day precision) at 50, 100 and 150 mg L -1 venlafaxine (n = 12). The experimental results verified the repeatability of the procedure, since the relative standard deviations were <1.0% in all cases.
Selectivity studies
The selectivity of the FI method was evaluated by studying the potential interfering effect of various concentrations of a placebo mixture (a mixture of all excipients except for the active ingredient) at a venlafaxine mass concentration of 50 mg L -1 . The placebo mixture contained per gram: 13.8 mg colloidal silica anhydrous, 896.3 mg dicalcium phosphate, 69.2 mg croscarmellose and 20.6 mg magnesium stearate. Appropriate amounts of the placebo mixture were dispersed in venlafaxine standard solutions (50 mg L -1 in 0.1 mol L -1 HCl) and sonicated for 10 min. The resulting solutions were analyzed after filtration through 0.45 µm disposable syringe filters. Although the maximum expected placebo concentration in real samples is ca. 300 mg L -1 , the selectivity experiments showed no interference even at the maximum tested concentration of 1000 mg L -1 .
Accuracy studies
In order to validate the accuracy of the assay, placebo solutions (containing 500 and 1000 mg L -1 placebo) were spiked with different amounts of venlafaxine covering the concentration range of the calibration curve. The usual sonication-filtration procedure was followed prior to each synthetic sample analysis. The experimental results shown in Table 2 verified the accuracy of the developed method, since the recoveries were in the range 98.0 -102.0% in all cases.
Application to dissolution studies
The proposed FI method was applied to dissolution studies of four venlafaxine validation batches. The strength of batches No. 370504-01 and -02 was 37.5 mg of the drug per tablet and the strength of batches No. 750504-01 and -02 was 75 mg per tablet. Dissolution experiments were performed under the conditions mentioned in Table 1 . The samples fractions were filtrated on-line through 45 µm filters and collected at 5, 10, 15 and 30 min intervals. Two typical dissolution profiles (batch No. 37050401) using FI and HPLC are depicted in Fig. 4 . The dissolution behavior of all batches was within the established limits (D > 80% at 30 min), while the FI results compared favorably to HPLC. The experimental results (at 30 min dissolution time) are given in Table 3 .
Conclusions
The present paper reports on the development, optimization and validation of a reliable FI procedure for the dissolution study of venlafaxine tablets. The proposed FI method is accurate, precise and adequately sensitive for the quality control of 1517 ANALYTICAL SCIENCES DECEMBER 2005, VOL. 21 venlafaxine formulations. The linearity and selectivity are satisfactory, while the FI method is six-times faster and more environmental friendly than HPLC. Another significant advantage of the FI method is that no additional pretreatment of the samples is required prior to the measuring step, thus accelerating the quality-control process. The results from analysis of real samples compared favorably to chromatography.
